10. May 2012 11:26
Pfizer’s Robert Clarke will leave his role as US regulatory strategy head to join Novo Nordisk in a similar position.
Mr Clarke will join Novo on 14 May to lead the Danish-based pharma company’s US regulatory team.
Anne Philips, Corporate Vice President of Clinical Development, Medical and Regulatory Affairs at Novo Nordisk, said the new recruit’s “know-how” is required by the diabetes specialist.
He will be tasked with maintaining relationships with key stakeholders and agencies that play a specific role in the FDA’s review and approval process.
“Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it’s that know-how we require for an increasingly complex pharmaceutical marketplace,” said Anne Philips.
“Novo Nordisk has one of the most promising diabetes pipelines in the industry, and having a respected leader known to regulatory authorities will help us achieve our ongoing mission to bring new therapies to patients.”